Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995680 | 0.81 | ALDH1A1 (0.30) | DGAT1 | |
| SCHEMBL2187338 | 0.80 | NPC1 (0.36) | TDP1CA12CA14DGAT1CA1 | |
| SCHEMBL14282687 | 0.80 | CTSK (0.41) | TDP1CA12CA14DGAT1CA1 | |
| SCHEMBL2911305 | 0.80 | CTSS (0.40) | TDP1DGAT1MEN1KMT2ACTSK | |
| SCHEMBL132657 | 0.75 | DGAT1 (0.42) | TDP1CA12CA14DGAT1CA1 | |
| SCHEMBL30154343 | 0.75 | MEN1 (0.35) | TDP1CA12CA14DGAT1CA1 | |
| SCHEMBL29957057 | 0.74 | CTSK (0.37) | TDP1CA12CA14DGAT1CA1 | |
| SCHEMBL15064823 | 0.73 | DGAT1 (0.41) | TDP1CA12CA14DGAT1CA1 | |
| Ammonia Solution, Strong SCHEMBL9998482 | 0.73 | DGAT1 (0.41) | TDP1CA12CA14DGAT1CA1 | |
| SCHEMBL13857890 | 0.73 | DGAT1 (0.41) | TDP1CA12CA14DGAT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
| US-6852856-B2 | Method for preserving quaternary ammonium salt | TOKUYAMA CORPORATION (JP) | 2005-02-08 | — | — | US | disclosed |
| US-6458948-B1 | MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC | TOKUYAMA CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-6123964-A | N-(1(R)-((1,2-DIHYDRO-1-METHANESULFONYLSPIRO(3H-INDOLE-3,4' -PIPERDIN)-1'-YL)CARBONYL)-2-(PHENYLMETHYLOXY)ETHYL)-2-AMINO-2-METHYL -PROPANAMIDE, SPECIFIED BINDER/DILUENT, FIRST AND SECOND DILUENTS, DISINTEGRANT, AND LUBRICANT(S); TABLETS | MERCK & CO., INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1019402-A1 | POLYMORPHIC FORMS OF A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6046333-A | Convergent process for the preparation of a growth hormone secretagogue | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-6028196-A | USING INEXPENSIVE AND ENVIRONMENTALLY ACCEPTABLE STARTING MATERIALS REAGENTS AND SOLVENTS, NO CHROMATOGRAPHIC PURIFICATION OF INTERMEDIATE SPIROINDOLINE SULFONAMIDE TO PRODUCE THE STIMULANTS FOR RELEASING SOMATOTROPIN | MERCK & CO., INC. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0857020-A4 | WET GRANULATION FORMULATION OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0863900-A1 | PROCESS FOR THE PREPARATION OF A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0857020-A1 | WET GRANULATION FORMULATION OF A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 1998-08-12 | — | — | EP | disclosed |
| US-5767124-A | ADMINISTERING TO HUMANS AND ANIMALS TO TREAT PHYSIOLOGICAL OR MEDICAL CONDITIONS CHARACTERIZED BY A DEFICIENCY IN GROWTH HORMONE SECRETION | MERCK & CO., INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5723616-A | Process for the preparation of a growth hormone secretagogue | MERCK & CO., INC. (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997015191-A1 | WET GRANULATION FORMULATION OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997015574-A1 | POLYMORPHIC FORMS OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997015573-A1 | PROCESS FOR THE PREPARATION OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |